A5040298712- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Synthesis and Biological Activity
- Pharmacogenetics and Drug Metabolism
- 14-3-3 protein interactions
- Chemical synthesis and alkaloids
- Biosimilars and Bioanalytical Methods
- PI3K/AKT/mTOR signaling in cancer
- Mast cells and histamine
- Enzyme function and inhibition
- Sarcoma Diagnosis and Treatment
- Phytochemistry and Bioactive Compounds
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Plant chemical constituents analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Ubiquitin and proteasome pathways
- Ferrocene Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
CSL (United States)
2025
PharmaMar (Spain)
2008-2017
Vifor Pharma (United States)
2014
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax) between RTXM83, a proposed rituximab biosimilar, its reference product, using population PK model approach.Rituximab PD data were obtained from randomized, double-blind, phase III clinical study (RTXM83-AC-01-11) patients with diffuse large B-cell lymphoma (DLBCL) that received 375 mg/m2 intravenous RTXM83 or product CHOP regimen, every 3 weeks, for six cycles. Rituximab levels...
Plitidepsin is a cyclic depsipeptide of marine origin in clinical development cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for adverse events (CAEs) that occurred trials with the single-agent plitidepsin. Demographic, and pharmacological variables explored by univariate multivariate logistic regression analysis. Forty-six 578 treated patients (8.0%) had at least one CAE (11 (1.9%) plitidepsin-related CAEs),...
Abstract Aim The aim of this study was to add robustness and provide further evidence on the bioequivalence, safety immunogenicity between MB02 reference bevacizumab. No similar has been performed before with a biosimilar monoclonal antibody. Methods Population analysis by pooling data from three independent pharmacokinetic (PK) studies performed. had single‐dose, double‐blind, three‐arm, parallel‐group design two studies, MB02‐A‐02‐17 MB02‐A‐05‐18, compared EU‐ US‐bevacizumab in Caucasian...
e13599 Background: Plitidepsin (Aplidin, APL) is a cyclic depsipeptide of marine origin in phase II/III development cancer patients (pts). It induces apoptosis through rapid and sustained JNK activation. Some depsipeptides have been linked to increased cardiac toxicity. Methods: Clinical databases were searched for adverse events (CAEs) studies with single-agent APL as Nov08. Demographic, clinical, pharmacological variables explored by univariate multivariate regression logistic analysis....